- Home
- GECC vs ANVS Comparison
GECC vs ANVS Comparison
Compare GECC & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GECC | ANVS |
|---|---|---|
| Founded | 2016 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.9M | 69.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | GECC | ANVS |
|---|---|---|
| Price | $6.17 | $1.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $10.75 | ★ $13.50 |
| AVG Volume (30 Days) | 91.0K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-12-2026 |
| Dividend Yield | ★ 22.06% | N/A |
| EPS Growth | N/A | ★ 39.39 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.92 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $1.54 |
| 52 Week High | $11.45 | $5.50 |
Technical Indicators
Market Signals| Indicator | GECC | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.87 | 43.64 |
| Support Level | $5.40 | $1.79 |
| Resistance Level | $7.16 | $2.57 |
| Average True Range (ATR) | 0.27 | 0.17 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 82.78 | 24.29 |
Price Performance
Historical ComparisonAbout GECC Great Elm Capital Corp.
Great Elm Capital Corp is an externally managed, non-diversified closed-end management investment company. It generates both income and capital appreciation through debt and income-generating equity investments, including investments in finance businesses. The Company operates as a single reportable segment with an investment objective to generate both current income and capital appreciation through debt and equity investments and manages the business on a consolidated basis.
About ANVS Annovis Bio Inc.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.